We recently caught up with Arndt Vogel from Hanover Medical University (Germany) to learn about clinically meaningful data from a pivotal Phase III study which indicates that lenvatinib is non-inferior to sorafenib in median overall survival for the first line systemic treatment of patients with unresectable hepatocellular carcinoma (HCC). In this interview you can find out about the current treatment options for unresectable HCC, the design and results of the REFLECT trial and the clinical significance of its findings.
What are the current treatment options for unresectable HCC?
Could you give us a brief overview of the REFLECT trial?
What was the reasoning behind making the trial a non-inferiority trial?
Could you tell us the main findings gathered from this trial?
What were the main differences in secondary end-points and/or side effects observed for lenvatinib and sorafenib?
What is the clinical significance of these findings?
What advancements do you hope to see in terms of treatment options for HCC in the next 5 years?
Professor Arndt Vogel is managing senior consultant and professor of gastrointestinal oncology in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (Director Prof. Dr. M.P. Manns). He is responsible for patients with gastrointestinal tumours, and is part of the liver transplantation and endoscopy team. He is leading a research group interested in the pathogenesis of hepatocellular carcinoma. Since 2004, Professor Vogel has been head of a research group focused on the molecular aspects of GI cancers. Several foundations and agencies, including the Deutsche Krebshilfe and Deutsche Forschungsgemeinschaft, fund his basic research. He is a Reviewer or Editor for many top-tier scientific journals and the author or coauthor of articles published in peer-reviewed journals including Cell, Cancer Cell, Gastroenterology, and Hepatology, as well as numerous book chapters.